CD47 and neoplasm: Moreover, Gholamin and colleagues have shown the promising therapeutic potential of targeting the CD47-SIRPα axis in patient-derived orthotopic xenograft models, where it reduces tumor growth in a variety of pediatric brain malignancies and inhibits metastasis (19).